West Pharmaceutical Services (WST) Non-Current Assets (2009 - 2026)

West Pharmaceutical Services has disclosed Non-Current Assets across 18 years of filings, most recently posting $2.3 billion for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $2.3 billion, up 5.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 billion (up 8.72% YoY), and the FY2025 annual result was $2.3 billion, up 8.86% from the prior year.
• Non-Current Assets came in at $2.3 billion for Q1 2026 at West Pharmaceutical Services, roughly flat from $2.3 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $2.3 billion in Q4 2025 to a low of $1.6 billion in Q3 2022.
• The 5-year median for Non-Current Assets is $1.9 billion (2024), against an average of $2.0 billion.
• Across the five-year window, Non-Current Assets advanced 2.52% in 2022 and grew 19.19% in 2024, its largest moves.
• West Pharmaceutical Services' Non-Current Assets stood at $1.7 billion in 2022, then advanced by 11.54% to $1.9 billion in 2023, then advanced by 11.21% to $2.1 billion in 2024, then advanced by 8.86% to $2.3 billion in 2025, then slipped by 0.38% to $2.3 billion in 2026.
• The last three Non-Current Assets figures came in at $2.3 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.3 billion (Q3 2025), per Business Quant data.